GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. Its prescription medicines range across therapeutic areas such as anti-infective, dermatology, gynecology, diabetes, cardiovascular disease and respiratory diseases. The vaccines products include prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia and others. The company was founded in 1924 and is headquartered in Mumbai, India.
GLAXOSMITHKLINE PHARMA LTD financial statements, including revenue, expenses, and profit: The total revenue of GLAXO for the last quarter is 8.05 B INR, and it's 17.37% lower compared to the previous quarter. The net income of Q1 25 is 2.05 B INR.
GLAXOSMITHKLINE PHARMA LTD key financial stats and ratios: GLAXO price-to-sales ratio is 14.33. The company has an Enterprise Value to EBITDA ratio of 44.66. As of 2024 they employed 3.11 k people.
GLAXOSMITHKLINE PHARMA LTD dividends overview: GLAXO dividends are paid annually. The last dividend per share was 42.00 INR. As of today, Dividend Yield (TTM)% is 1.33%.
GLAXOSMITHKLINE PHARMA LTD revenue breakdown overview: GLAXOSMITHKLINE PHARMA LTD revenue for the last year amounted to 37.49 B INR, the most of which — 37.49 B INR — came from its highest performing source at the moment, Pharmaceuticals, the year earlier bringing 34.54 B INR. The greatest contribution to the revenue figure was made by India — last year it brought GLAXOSMITHKLINE PHARMA LTD 36.99 B INR, and the year before that — 33.92 B INR.
Potential 50% Upside with Entry Price 2900, Target Price 4350, Timeframe 6-12 Months
Comments
Post a Comment